한글목차

피하 면역글로불린(SCIG) 시장 규모는 최근 급성장하고 있습니다. 2025년 143억 9,000만 달러에서 2026년에는 163억 2,000만 달러에 이르고, CAGR 13.4%의 성장이 전망되고 있습니다. 지난 수년간의 성장에는 원발성 면역결핍증 진단 증가, 정맥 내 면역글로불린 치료의 한계, 장기 면역 지원의 필요성 증가, SCIG의 안전성 프로파일 개선, 재택 치료를 선호하는 환자 증가 등이 주요 요인으로 작용한 것으로 보입니다.

피하 면역글로불린(SCIG) 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 257억 1,000만 달러에 이르고, CAGR은 12.0%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 면역 결핍증 이외의 SCIG 적응증 확대, 재택치료 요법에 대한 의료 현장의 관심 증가, 수액 장치의 기술 발전, 자가 면역 질환 및 신경 질환의 유병률 증가, 환자 중심 치료 모델에 대한 수요 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 정맥 내 면역글로불린 요법(IVIG)에서 피하 면역글로불린 요법(SCIG)으로의 전환 증가, 재택 면역글로불린 치료의 도입 확대, 자가 투여 기기의 선호도 증가, 만성 면역 질환에 대한 SCIG 사용 확대, 장기 면역 대체 요법에 대한 수요 증가 등이 있습니다. 등을 꼽을 수 있습니다.

이차성 면역 결핍 질환의 유병률 증가는 향후 몇 년 동안 피하 면역글로불린 시장의 성장을 견인할 것으로 예측됩니다. 이차성 면역 결핍 질환은 면역계 자체 이외의 요인에 의해 면역기능이 약화되거나 손상된 상태를 말합니다. 이러한 질환 증가에는 고령화, 면역억제요법 사용, 환경독소 노출 등 다양한 요인이 영향을 미치고 있습니다. 피하 면역글로불린 요법은 특히 HIV나 자가면역질환과 같은 만성질환에서 약화된 면역체계를 지원하는 항체를 공급하여 치료 중 감염 예방과 면역기능을 강화하는 치료법입니다. 예를 들어, 영국에 기반을 둔 치료 활동 단체 'HIV i-Base'에 따르면, 2024년 10월 기준 이성애 남성의 신규 HIV 감염자 수는 2022년 445명에서 605명으로 36% 증가, 이성애 여성은 2022년 602명에서 780명으로 30% 증가했습니다. 그 결과, 이차성 면역결핍질환의 유병률 증가가 피하투여형 면역글로불린 시장 확대에 기여하고 있습니다.

신경 질환의 유병률 증가는 향후 몇 년 동안 피하 면역글로불린 시장의 성장을 견인할 것으로 예측됩니다. 신경질환이란 급성척수손상, 알츠하이머형 치매, 근위축성 측색경화증(ALS), 운동실조증, 뇌종양 등을 포함하여 뇌, 척수, 말초신경의 해부학적, 생화학적, 전기적 이상을 동반한 신경계에 영향을 미치는 모든 병태를 말합니다. 신경질환 증가는 고령화, 환경독소, 유전적 소인, 생활습관 변화 등의 요인에 기인합니다. 피하 면역글로불린 요법은 면역반응을 조절하고 염증을 감소시키며 신경근 접합부를 안정화시키는 항체를 공급함으로써 신경질환에 효과적이며, 질환의 진행을 지연시키고 증상을 완화시킬 수 있습니다. 예를 들어, 2023년 3월 미국 비영리 건강단체 '알츠하이머 협회'가 발표한 자료에 따르면 65세 이상 미국인 670만 명이 알츠하이머형 치매를 앓고 있으며, 2060년까지 1,380만 명에 달할 것으로 예측했습니다. 이러한 신경질환의 유병률 증가는 피하면역글로불린 시장의 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Subcutaneous immunoglobulin (SCIG) is a method of giving immunoglobulin therapy in which the medication is injected under the skin rather than into a vein. This approach allows the medication to be absorbed more slowly, lowering the risk of side effects compared to intravenous administration. SCIG is employed to manage various immune deficiencies, offering a convenient and effective way to strengthen the immune system.

The main types of subcutaneous immunoglobulin (SCIG) products include immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM). IgA is an antibody that plays a vital role in immune defense at mucosal surfaces, helping to prevent pathogens from entering the body through mucous membranes. These products are used for various applications, such as primary immunodeficiency disorders, autoimmune diseases, neurological disorders, and others, and are utilized by a range of end-users, including clinics, hospitals, homecare, and more.

Tariffs have influenced the scig market by increasing costs of plasma-derived immunoglobulins, infusion pumps, and medical-grade consumables. These impacts are most significant in regions reliant on imported plasma products and specialized delivery devices. Higher tariffs may affect treatment affordability and reimbursement dynamics. However, tariffs are encouraging plasma fractionation investments, regional manufacturing expansion, and supply chain localization.

The subcutaneous immunoglobulin (scig) market research report is one of a series of new reports from The Business Research Company that provides subcutaneous immunoglobulin (scig) market statistics, including subcutaneous immunoglobulin (scig) industry global market size, regional shares, competitors with a subcutaneous immunoglobulin (scig) market share, detailed subcutaneous immunoglobulin (scig) market segments, market trends and opportunities, and any further data you may need to thrive in the subcutaneous immunoglobulin (scig) industry. This subcutaneous immunoglobulin (scig) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The subcutaneous immunoglobulin (scig) market size has grown rapidly in recent years. It will grow from $14.39 billion in 2025 to $16.32 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to rising diagnosis of primary immunodeficiency disorders, limitations of intravenous immunoglobulin therapy, increasing need for long-term immune support, improved safety profile of scig, growing patient preference for at-home care.

The subcutaneous immunoglobulin (scig) market size is expected to see rapid growth in the next few years. It will grow to $25.71 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to expansion of scig indications beyond immunodeficiency, increasing healthcare focus on homecare therapies, technological advancements in infusion devices, growing prevalence of autoimmune and neurological disorders, rising demand for patient-centric treatment models. Major trends in the forecast period include growing shift from ivig to scig therapies, rising adoption of home-based immunoglobulin treatment, increasing preference for self-administration devices, expansion of scig use in chronic immune disorders, higher demand for long-term immune replacement therapy.

The rising prevalence of secondary immunodeficiency diseases is expected to drive the growth of the subcutaneous immunoglobulin market in the coming years. Secondary immunodeficiency diseases are conditions in which the immune system is weakened or compromised due to factors external to the immune system itself. The increase in these diseases is influenced by various factors, including aging populations, the use of immunosuppressive therapies, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy delivers antibodies to support the weakened immune system, particularly in chronic conditions such as HIV or autoimmune disorders, thereby preventing infections and enhancing immune function during treatment. For example, in October 2024, according to HIV i-Base, a UK-based treatment activist organization, new HIV diagnoses rose by 36% among heterosexual men, increasing from 445 in 2022 to 605, and by 30% among heterosexual women, rising from 602 in 2022 to 780. Consequently, the growing prevalence of secondary immunodeficiency diseases is contributing to the expansion of the subcutaneous immunoglobulin market.

The rising prevalence of neurological disorders is anticipated to drive the growth of the subcutaneous immunoglobulin market in the coming years. A neurological disorder refers to any condition affecting the nervous system, involving anatomical, biochemical, or electrical abnormalities in the brain, spinal cord, or peripheral nerves, including acute spinal cord injury, Alzheimer's dementia, amyotrophic lateral sclerosis (ALS), ataxia, brain tumors, and others. The increase in neurological disorders is attributed to factors such as aging populations, environmental toxins, genetic predispositions, and lifestyle changes. Subcutaneous immunoglobulin therapy can be effective in neurological disorders by supplying antibodies that regulate the immune response, reduce inflammation, and stabilize neuromuscular junctions, potentially slowing disease progression and alleviating symptoms. For example, in March 2023, the Alzheimer's Association, a US-based nonprofit voluntary health organization, reported that 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, with projections suggesting this number could reach 13.8 million by 2060. Consequently, the growing prevalence of neurological disorders is fueling the expansion of the subcutaneous immunoglobulin market.

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are concentrating on developing innovative solutions, such as ready-to-use prefilled formulations, to improve treatment convenience, facilitate self-administration, and enhance the overall patient experience. Ready-to-use SCIG formulations are premeasured, stable immunoglobulin products intended for subcutaneous administration, enabling patients with primary immunodeficiency and other immune disorders to receive therapy more easily outside clinical environments. For example, in April 2023, the U.S. Food and Drug Administration (FDA) approved a 50 mL / 10 g prefilled syringe version of Hizentra (Immune Globulin Subcutaneous [Human] 20%), offering patients a simplified, ready-to-use option that allows more convenient home infusion and supports better treatment adherence.

Major companies operating in the subcutaneous immunoglobulin (scig) market are CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, Biotest AG, Bio Products Laboratory Ltd., ADMA Biologics Inc., Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bharat Serums and Vaccines Limited, Emergent BioSolutions Inc., Pfizer Inc., Johnson & Johnson, Lonza Group, Argenx SE, CinnaGen Co., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd.

North America was the largest region in the subcutaneous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (scig) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the subcutaneous immunoglobulin (scig) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The subcutaneous immunoglobulin (SCIG) market consists of revenues earned by entities by providing services such as immune system support, home-based therapy, infection prevention, personalized dosing, patient training, and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The subcutaneous immunoglobulin market also includes sales of infusion pumps, needles and catheters, syringes, and sharps disposal containers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Subcutaneous Immunoglobulin (SCIG) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses subcutaneous immunoglobulin (scig) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for subcutaneous immunoglobulin (scig) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The subcutaneous immunoglobulin (scig) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Immunoglobulin A (IgA); Immunoglobulin G (IgG)
• 2) By Application: Primary Immunodeficiency Disorders; Autoimmune Diseases; Neurological Disorders; Other Applications
• 3) By End-Use: Clinics; Hospitals; Homecare; Other End-Uses
• Subsegments:
• 1) By Immunoglobulin A (IgA): IgA1; IgA2
• 2) By Immunoglobulin G (IgG): IgG1; IgG2; IgG3; IgG4
• Companies Mentioned: CSL Behring; Grifols S.A.; Octapharma AG; Kedrion Biopharma; LFB Group; Biotest AG; Bio Products Laboratory Ltd.; ADMA Biologics Inc.; Kamada Pharmaceuticals; Takeda Pharmaceutical Company Limited; Baxter International Inc.; Bharat Serums and Vaccines Limited; Emergent BioSolutions Inc.; Pfizer Inc.; Johnson & Johnson; Lonza Group; Argenx SE; CinnaGen Co.; Intas Pharmaceuticals Ltd.; Dr. Reddy's Laboratories Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Subcutaneous Immunoglobulin (SCIG) Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Subcutaneous Immunoglobulin (SCIG) Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Subcutaneous Immunoglobulin (SCIG) Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Subcutaneous Immunoglobulin (SCIG) Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Growing Shift From IVIG To SCIG Therapies
  • 4.2.2 Rising Adoption Of Home-Based Immunoglobulin Treatment
  • 4.2.3 Increasing Preference For Self-Administration Devices
  • 4.2.4 Expansion Of SCIG Use In Chronic Immune Disorders
  • 4.2.5 Higher Demand For Long-Term Immune Replacement Therapy

5. Subcutaneous Immunoglobulin (SCIG) Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare Settings
• 5.4 Immunology Centers
• 5.5 Neurology Clinics

6. Subcutaneous Immunoglobulin (SCIG) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Subcutaneous Immunoglobulin (SCIG) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Subcutaneous Immunoglobulin (SCIG) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Subcutaneous Immunoglobulin (SCIG) Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Subcutaneous Immunoglobulin (SCIG) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Subcutaneous Immunoglobulin (SCIG) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Subcutaneous Immunoglobulin (SCIG) Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Subcutaneous Immunoglobulin (SCIG) Market Segmentation

• 9.1. Global Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immunoglobulin A (IgA), Immunoglobulin G (IgG)
• 9.2. Global Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
• 9.3. Global Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Clinics, Hospitals, Homecare, Other End-Uses
• 9.4. Global Subcutaneous Immunoglobulin (SCIG) Market, Sub-Segmentation Of Immunoglobulin A (IgA), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• IgA1, IgA2
• 9.5. Global Subcutaneous Immunoglobulin (SCIG) Market, Sub-Segmentation Of Immunoglobulin G (IgG), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• IgG1, IgG2, IgG3, IgG4

10. Subcutaneous Immunoglobulin (SCIG) Market Regional And Country Analysis

• 10.1. Global Subcutaneous Immunoglobulin (SCIG) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Subcutaneous Immunoglobulin (SCIG) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Subcutaneous Immunoglobulin (SCIG) Market

• 11.1. Asia-Pacific Subcutaneous Immunoglobulin (SCIG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Subcutaneous Immunoglobulin (SCIG) Market

• 12.1. China Subcutaneous Immunoglobulin (SCIG) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Subcutaneous Immunoglobulin (SCIG) Market

• 13.1. India Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Subcutaneous Immunoglobulin (SCIG) Market

• 14.1. Japan Subcutaneous Immunoglobulin (SCIG) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Subcutaneous Immunoglobulin (SCIG) Market

• 15.1. Australia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Subcutaneous Immunoglobulin (SCIG) Market

• 16.1. Indonesia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Subcutaneous Immunoglobulin (SCIG) Market

• 17.1. South Korea Subcutaneous Immunoglobulin (SCIG) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Subcutaneous Immunoglobulin (SCIG) Market

• 18.1. Taiwan Subcutaneous Immunoglobulin (SCIG) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Subcutaneous Immunoglobulin (SCIG) Market

• 19.1. South East Asia Subcutaneous Immunoglobulin (SCIG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Subcutaneous Immunoglobulin (SCIG) Market

• 20.1. Western Europe Subcutaneous Immunoglobulin (SCIG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Subcutaneous Immunoglobulin (SCIG) Market

• 21.1. UK Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Subcutaneous Immunoglobulin (SCIG) Market

• 22.1. Germany Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Subcutaneous Immunoglobulin (SCIG) Market

• 23.1. France Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Subcutaneous Immunoglobulin (SCIG) Market

• 24.1. Italy Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Subcutaneous Immunoglobulin (SCIG) Market

• 25.1. Spain Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Subcutaneous Immunoglobulin (SCIG) Market

• 26.1. Eastern Europe Subcutaneous Immunoglobulin (SCIG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Subcutaneous Immunoglobulin (SCIG) Market

• 27.1. Russia Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Subcutaneous Immunoglobulin (SCIG) Market

• 28.1. North America Subcutaneous Immunoglobulin (SCIG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Subcutaneous Immunoglobulin (SCIG) Market

• 29.1. USA Subcutaneous Immunoglobulin (SCIG) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Subcutaneous Immunoglobulin (SCIG) Market

• 30.1. Canada Subcutaneous Immunoglobulin (SCIG) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Subcutaneous Immunoglobulin (SCIG) Market

• 31.1. South America Subcutaneous Immunoglobulin (SCIG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Subcutaneous Immunoglobulin (SCIG) Market

• 32.1. Brazil Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Subcutaneous Immunoglobulin (SCIG) Market

• 33.1. Middle East Subcutaneous Immunoglobulin (SCIG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Subcutaneous Immunoglobulin (SCIG) Market

• 34.1. Africa Subcutaneous Immunoglobulin (SCIG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Subcutaneous Immunoglobulin (SCIG) Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Subcutaneous Immunoglobulin (SCIG) Market Regulatory and Investment Landscape

36. Subcutaneous Immunoglobulin (SCIG) Market Competitive Landscape And Company Profiles

• 36.1. Subcutaneous Immunoglobulin (SCIG) Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Subcutaneous Immunoglobulin (SCIG) Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Subcutaneous Immunoglobulin (SCIG) Market Company Profiles
  • 36.3.1. CSL Behring Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Grifols S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Octapharma AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Kedrion Biopharma Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. LFB Group Overview, Products and Services, Strategy and Financial Analysis

37. Subcutaneous Immunoglobulin (SCIG) Market Other Major And Innovative Companies

• Biotest AG, Bio Products Laboratory Ltd., ADMA Biologics Inc., Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bharat Serums and Vaccines Limited, Emergent BioSolutions Inc., Pfizer Inc., Johnson & Johnson, Lonza Group, Argenx SE, CinnaGen Co., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd.

38. Global Subcutaneous Immunoglobulin (SCIG) Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Subcutaneous Immunoglobulin (SCIG) Market

40. Subcutaneous Immunoglobulin (SCIG) Market High Potential Countries, Segments and Strategies

• 40.1 Subcutaneous Immunoglobulin (SCIG) Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Subcutaneous Immunoglobulin (SCIG) Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Subcutaneous Immunoglobulin (SCIG) Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer